[Long-term administration study on TE-031 (A-56268) in the treatment of diffuse panbronchiolitis].
TE-031 (A-56268), a new macrolide antibiotics, was administered on a long-term basis (6 months) to 12 patients with diffuse panbronchiolitis (DPB). The causative microorganism was identified as H. influenzae in 5 cases, P. aeruginosa in 4 cases and B. catarrhalis in one case. The clinical picture of those patients was monitored, and some basic studies were also carried out. Clinically, all of the patients showed improvement in the symptoms and the various laboratory test values. Bacteriologically, as well, both H. influenzae and B. catarrhalis were eradicated. In addition, P. aeruginosa was eradicated from 2 of the 4 cases, reduced in one case and unchanged in one case. However, even in that one case in which P. aeruginosa was unchanged, the disease symptoms were alleviated. There were no instance of microbial replacement. In spite of the long-term administration of TE-031, There were no side effects. As the basic study, the DPB patients were examined for the presence of antibodies directed at viruses having affinity for the respiratory organs. It was found that a high percentage of the patients showed a high titer of antibodies for influenza virus type III and type II. It was thus surmised that it is likely that viral infection is involved in the progress of this disease. From the standpoint of the progress of DPB, the NK activity was investigated as part of the natural host defense mechanisms. It was found that, compared with healthy controls, the level of NK activity was higher in DPB patients and that it was even higher in patients on long-term TE-031 administration.(ABSTRACT TRUNCATED AT 250 WORDS)
Takeda
H
H
Miura
H
H
Kawahira
M
M
Kobayashi
H
H
Otomo
S
S
Nakaike
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy / Q000276:immunology; D001991:Bronchitis / Q000188:drug therapy* / Q000276:immunology; D017291:Clarithromycin; D004917:Erythromycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D004917:Erythromycin; D017291:Clarithromycin